Reach Us +44-1904-929220
Therapeutic Targets in Breast Cancer Stem Cells | OMICS International | Abstract

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Therapeutic Targets in Breast Cancer Stem Cells

Alfredo Amador-Molina1, S. Mayra Pérez-Tapia2 and Marco A. Velasco-Velázquez3*

1Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología, México D.F., México

2Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional. México D.F., México

3Departamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México. Apdo. Postal 70-297, Ciudad Universitaria, México D.F. 04510, México

*Corresponding Author:
Marco A. Velasco-Velázquez
Departamento de Farmacología
Facultad de Medicina, UNAM
Apdo. Postal 70-297
Ciudad Universitaria. México D.F. 04510, México
Tel: + (52-55) 5623-2282
Fax: + (52-55) 5616-1489
E-mail: [email protected]

Received date: May 22, 2012; Accepted date: August 01, 2012; Published date: August 03, 2012

Citation: Amador-Molina A, Pérez-Tapia SM, Velasco-Velázquez MA (2012) Therapeutic Targets in Breast Cancer Stem Cells. J Mol Biomarkers Diagn S8:005. doi:10.4172/2155-9929.S8-005

Copyright: © 2012 Amador-Molina A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited


Breast cancer stem cells (BCSCs) constitute a subpopulation of tumor cells with self-renewal capability,
expression of stem cell-like markers, and increased tumorigenicity in vivo. Clinical evidence has shown that BCSCs
play a major role in the initiation, maintenance, and outcome of breast tumors. Therefore, BCSCs have been identified
as ideal targets for the development of new therapies. Such therapies must consider the phenotypical differences
between BCSCs cells, non-stem tumor cells, and normal cells. This review summarizes different strategies for
BCSCs eradication that have been employed in preclinical assays, including: i) targeting proteins differentially
expressed such as surface markers, transporters, or enzymes; ii) inhibiting self-renewal pathways; and iii) blocking
the interaction of the BCSCs with their niche. These approaches may become the basis for the generation of effective
and clinically applicable therapies that prevent disease relapse, metastasis, and enhance patient survival.


Recommended Conferences

15th Global Biomarkers and Clinical Research Summit

Vienna, Austria

2nd International Conference on Biomarkers and Cancer Targets

Capetown, South Africa
Share This Page